Level Zero Health funding news – London-based HealthTech Startup Level Zero Health Secures €6.6 Million in Pre-Seed Funding

Ula Rustamova, CEO of Level Zero Health, comments: “Our innovative remote monitoring technology marks an enormous leap forward in hormone testing, and this funding will enable us to bring this revolutionary solution to market. This breakthrough in health technology has come about in a relatively short amount of time, but already we are seeing strong demand from customers who recognise the benefits of hormone monitoring not only because it allows patients to skip invasive and inconvenient lab tests, but also because it captures critical data inaccessible before.”

Level Zero Health has formed a team of expert advisors, including Aaron Styer, medical director at CCRM Fertility and a Harvard Medical School professor, Kelly Walker, a urologist and medical advisor at hims, and Joshua Klein, medical director at Extend Fertility and assistant professor at Icahn School of Medicine.

Typically, hormone tests rely on blood samples, which only provide a snapshot of hormone levels at one point in time and need special equipment and expertise.

Level Zero Health is changing this with its technology that allows remote and continuous hormone monitoring, providing new ways to understand how our body works.

Instead of using blood samples, their DNA-based sensors measure hormone levels in interstitial fluid – the fluid that surrounds cells and tissues. In less than a year, the company has tested its sensors in 98% of the human clinical range, exceeding industry standards.

Read also - Pixel Photonics funding news – Munster-based DeepTech Startup Pixel Photonics Secures €1 Million in Funding

Level Zero Health uses biochemistry and nanotechnology to create a sleek, minimally invasive wearable patch. Similar to glucose monitors, the device attaches to the user's arm and provides real-time readings of stress and reproductive hormones.

This technology could change healthcare in areas like IVF, menopause, and testosterone replacement therapy (TRT).

The company will use the funding for research, developing the product, and growing its team. While it will first focus on B2B clinical uses, it plans to expand into B2C and pharma markets in the future.

Philip Kneis, investor at redalpine and board member of Level Zero Health, said: “We did it for blood pressure and will do it again for hormones. Continuous hormone measurement is one of the holy grails of diagnostics, and as fundamental science transitions to engineering, we couldn’t be more excited to back Level Zero Health in their mission to transform hormone tracking with their novel biosensor – paving the way for a new era of personalized health management.”

Aaron Styer MD, Co-founding partner and medical director at CCRM Fertility Boston comments: “Improvements in healthcare delivery have been impacted by the limitations of existing devices and applications. This technological breakthrough by Level Zero Health will transform the clinician’s ability to manage and monitor hormonal-based diseases and treatments. The technology has a myriad of applications across remote hormonal monitoring for fertility treatments and endocrine disorders. It will significantly expand patient access to care, reduce healthcare costs, and enable clinicians to change the paradigm of medical practice.”

About Level Zero Health

Level Zero Health was founded in 2023 by Ula Rustamova, a former tech lead at Palantir, and Irene Jia, who worked on medical devices at Philips. The company focuses on creating wearable technology for hormone health and uses unique methods for remote, continuous hormone monitoring.